Rhinitis Allergic Clinical Trial
Official title:
A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort® Nasal Spray (Triamcinolone, 55µg) in Comparison With Flixonase® Nasal Spray (Fluticasone, 50 µg) in Adults Suffering From PAR (Perennial Allergic Rhinitis) Administered Once a Day for 28 Days
Primary Objective: - To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after 28 days of treatment compared with baseline (0 day of treatment) in adult patients suffering from PAR (perennial allergic rhinitis). Secondary Objectives: - To evaluate safety of Nasacort® (triamcinolone) nasal spray, in comparison with Flixonase® (fluticasone) administered for 28 days by assessment of adverse events reports. - To evaluate patient and physician satisfaction after 28 days of treatment by 5-point scale. - To estimate improvement of quality of life during the study by mini Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ).
The total study duration per patient will be up to approximately 33 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02401191 -
A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis
|
Phase 3 | |
| Completed |
NCT00380705 -
Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)
|
Phase 4 | |
| Completed |
NCT02175485 -
Evaluation of Efficacy of Dellegra in Exposure Unit
|
Phase 4 | |
| Completed |
NCT01385371 -
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
|
Phase 3 | |
| Not yet recruiting |
NCT05720455 -
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
|
Phase 4 | |
| Completed |
NCT00446186 -
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
|
Phase 2 |